Last updated on June 2019

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)


Brief description of study

This is a Phase 1/1b dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Clinical Study Identifier: NCT02500407

Find a site near you

Start Over

Tennessee Oncology

Nashville, TN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

New York Uni Medical Center

New York, NY United States
  Connect »

The Alfred

Melbourne, Australia
  Connect »

Sansum Medical Clinic, Inc.

Santa Barbara, CA United States
  Connect »

Barts Cancer Institute

London, United Kingdom
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.